Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the association between mood stabilizers and alopecia, providing diagnosis insights and management options, but reports no new clinical results.

This article discusses the potential for severe adverse cutaneous drug reactions with mood-stabilizing agents, emphasizing the importance of monitoring and patient communication, but reports no new clinical findings.

This systematic review and meta-analysis found that mood stabilizers used for bipolar disorder, such as lithium, valproate, carbamazepine, and lamotrigine, resulted in varying prevalence of dermatologic side effects, with lamotrigine showing the highest rash incidence, while severe reactions were rare.

This review provides an overview of the prevalence and management of side effects of mood-stabilizing drugs in bipolar disorder patients and reports no new clinical results.

This review discusses the guidelines for using and monitoring mood stabilizers in bipolar disorders, highlighting that only a minority of patients receive guideline-adherent monitoring.

This review discusses the potential for mood stabilizers, antidepressants, and some antipsychotic and antianxiety drugs to induce alopecia and reports no clinical results.

This review discusses the challenges of diagnosing and treating pediatric bipolar disorder and highlights the potential benefits of combined psychopharmacological treatments, noting no long-term efficacy from mood stabilizer monotherapy.

This review discusses various psychiatric treatments including antipsychotics, insomnia medication, and mood stabilizers, but reports no new clinical results; the authors comment on existing findings and approvals.

This report discusses that curly hair is a very rare side effect of valproate, a medication used as a mood stabilizer for bipolar disorder, though such drug-induced hair changes are uncommon.

This article reviews the uses, mechanisms, and side effects of valproate in treating bipolar disorder, noting its first-line status for several manic conditions but also highlighting serious risks such as fetal abnormalities.

This review examines the dermatologic side effects of lithium, noting it can cause or worsen skin conditions like psoriasis and acne, potentially affecting medication adherence, but reports no new clinical results.

This correspondence article discusses a case of androgenetic alopecia treated with valproic acid but does not present new clinical findings.

This review discusses the role of histone deacetylases in hearing loss, proposing potential pharmacological interventions, but reports no new clinical results.

This article reviews the association between psychopharmaceuticals and medication-induced alopecia, noting that hair regrowth typically occurs after discontinuing or reducing the medication, while mineral supplements' effectiveness remains unclear.

This review discusses cutaneous adverse effects of psychotropic medications and reports no new findings, emphasizing the importance of psychiatrists being aware of these potential skin reactions.

Valproate can cause both hair loss and curly hair in bipolar disorder patients.

Agomelatine might help stop hair loss caused by valproate.

This study found that topical valproate has minimal potential to cause skin irritation, suggesting it can be applied safely to human skin.

This review explores how psychotropic medications can cause a range of skin reactions, from mild to life-threatening, and emphasizes the importance of monitoring for these adverse effects early in treatment.

This study found that acute sleep deprivation enhanced 5α-reductase expression and activity in the rat prefrontal cortex, and finasteride treatment reduced associated psychosis- and mania-like behaviors.

This study suggests that measuring cortisol levels in hair may serve as a useful biomarker for assessing mood in individuals with bipolar disorder over recent months.

This study observed that six sessions of injections using a stabilized hyaluronic acid compound improved hair thickness, shine, density, and reduced hair loss in volunteers with moderate androgenetic alopecia, with excellent treatment tolerability and high satisfaction reported by 88.5% of participants.

This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.

In this study, Saudi Arabian adults experienced high rates of long-term complications and significant weight regain more than 5 years after bariatric surgery, emphasizing the need for ongoing follow-up and nutritional management to address these issues.

In this study, high-dose dutasteride significantly reduced several core symptoms of PMDD compared to placebo, supporting the role of neurosteroids in this condition.

This case study reports the first documentation of the intermittent nature of chronic telogen effluvium and suggests a link between emotional stress and hair shedding severity.

In this study, a case of a 70-year-old woman with central centrifugal cicatricial alopecia showed that using a high-quality hair prosthesis improved her quality of life and mood, as measured by PHQ-9 and Skindex-29 scores, though such wigs are rarely covered by insurance.

This chapter discusses the sources, classifications, and effects of hormones, their role in disease treatment and food security, and reports no new results.

In this review, researchers found that TNF-α, IL-17, and JAK inhibitors show the most promise for stabilizing and resolving scarring alopecias, with IL-23 and Interferon Alpha Receptor 1 inhibitors also providing some benefits in managing these hair loss conditions.

The document concludes that individualized treatment and lifestyle changes are important for managing menopause symptoms and health risks.